{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-126288","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.445683+00:00","generated_at":"2026-05-30T00:59:47.750987+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Equillium Q3 revenue $12.2M, net loss near zero; retains itolizumab rights after Ono termination","bullets":["Q3 revenue $12.2M (up 37% YoY) from Ono partnership; net loss ~$7,000 vs $3.7M loss in Q3 2023.","Cash $25.9M; sufficient into Q4 2025 assuming accelerated EQUATOR study, pausing EQ101/EQ302, and cost reductions.","Ono partnership ended after substantial non-dilutive funding; Equillium retains full rights to itolizumab.","Phase 3 EQUATOR aGVHD study enrollment paused; potential topline acceleration to Q1 2025.","Partner Biocon completed Phase 2 ulcerative colitis study; topline data expected Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-126288","json":"https://secwatch.observer/filing/0000950170-24-126288.json","markdown":"https://secwatch.observer/filing/0000950170-24-126288.md","text":"https://secwatch.observer/filing/0000950170-24-126288.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000095017024126288/0000950170-24-126288-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000095017024126288/eq-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:59:47.750987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}